טוען...
Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action
The recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-M...
שמור ב:
| הוצא לאור ב: | Best Pract Res Clin Haematol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7060936/ https://ncbi.nlm.nih.gov/pubmed/32139009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2020.101143 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|